Skip to main content Skip to section navigation Skip to footer
Vivani Medical, Inc.
  • Investors
  • IR Overview
  • News & Events
    • Overview
    • Press Releases
    • In the News
    • IR Calendar
    • Presentations
    • Email Alerts
  • Our Company
    • Overview
    • Executive Leadership
    • Code of Ethics
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Annual Reports & Proxy Statements
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
    • Privacy

Press Releases

News & Events

News & Events

  • Overview
  • Press Releases
  • In the News
  • IR Calendar
  • Presentations
  • Email Alerts
      May 29, 2025 8:30am EDT

      Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders

      May 13, 2025 4:30pm EDT

      Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

      May 07, 2025 8:30am EDT

      Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

      Apr 16, 2025 8:30am EDT

      Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company

      Apr 15, 2025 8:30am EDT

      Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

      Mar 31, 2025 7:30am EDT

      Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Mar 27, 2025 7:32am EDT

      Vivani Medical Announces $8.25M Private Placement Equity Financing

      Mar 26, 2025 7:30am EDT

      Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

      Mar 24, 2025 8:30am EDT

      Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025

      Mar 13, 2025 7:30am EDT

      Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

      • Page 1
      • Page 2
      • Page 3
      • Page 4
      • Page 5
      • Page 6
      • Page 7
      • Page 8
      • Page 9
      • Page 10
      • …
      • Page 20
      • Next Pagearrow_forward
      rss_feed News RSS
      • Email Alerts
      • Contacts
      • RSS News Feed
      ©2025 Vivani Medical, Inc. All Rights Reserved.
      Privacy Policy Disclaimer Sitemap